[
  {
    "ts": null,
    "headline": "H.C. Wainwright Raises Protagonist Therapeutics, Inc. (PTGX) Target to $117, Reiterates Buy",
    "summary": "We recently published an article titled 10 Best Long Term Healthcare Stocks to Buy. On January 30, H.C. Wainwright raised its price target on Protagonist Therapeutics, Inc. (NASDAQ:PTGX) to $117 from $80 and reiterated a Buy rating. The firm cited the company’s track record in drug development and assigned probability-of-success assumptions across multiple programs, including […]",
    "url": "https://finnhub.io/api/news?id=a780ca121fe46325df27aef061fcbe4e4589d4e199c33c97e82f8c6a566262aa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770840795,
      "headline": "H.C. Wainwright Raises Protagonist Therapeutics, Inc. (PTGX) Target to $117, Reiterates Buy",
      "id": 139049473,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "We recently published an article titled 10 Best Long Term Healthcare Stocks to Buy. On January 30, H.C. Wainwright raised its price target on Protagonist Therapeutics, Inc. (NASDAQ:PTGX) to $117 from $80 and reiterated a Buy rating. The firm cited the company’s track record in drug development and assigned probability-of-success assumptions across multiple programs, including […]",
      "url": "https://finnhub.io/api/news?id=a780ca121fe46325df27aef061fcbe4e4589d4e199c33c97e82f8c6a566262aa"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson Files For Debt Shelf, Size Not Disclosed",
    "summary": "https://www.sec.gov/Archives/edgar/data/200406/000119312526046865/d80821ds3asr.htm",
    "url": "https://finnhub.io/api/news?id=baf5fdb53cd37dcb0e50306b2b7a7d52989b060aea3f71d9d8dfed562b419260",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770834589,
      "headline": "Johnson & Johnson Files For Debt Shelf, Size Not Disclosed",
      "id": 139055680,
      "image": "",
      "related": "JNJ",
      "source": "Benzinga",
      "summary": "https://www.sec.gov/Archives/edgar/data/200406/000119312526046865/d80821ds3asr.htm",
      "url": "https://finnhub.io/api/news?id=baf5fdb53cd37dcb0e50306b2b7a7d52989b060aea3f71d9d8dfed562b419260"
    }
  },
  {
    "ts": null,
    "headline": "Should You Buy ISRG Stock Despite a 13% Fall in Three Months?",
    "summary": "ISRG has lost 13% in three months, but strong da Vinci 5 adoption and rising procedures raise a bigger question: is this pullback a buying opportunity?",
    "url": "https://finnhub.io/api/news?id=93268816836bfd59f611cac98d19c5a4b833452af2d362343a346657330a2f9b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770826440,
      "headline": "Should You Buy ISRG Stock Despite a 13% Fall in Three Months?",
      "id": 139048026,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "ISRG has lost 13% in three months, but strong da Vinci 5 adoption and rising procedures raise a bigger question: is this pullback a buying opportunity?",
      "url": "https://finnhub.io/api/news?id=93268816836bfd59f611cac98d19c5a4b833452af2d362343a346657330a2f9b"
    }
  },
  {
    "ts": null,
    "headline": "NIH Stops Johnson & Johnson's Blood Thinner Drug Arm In Stroke Trial After Safety Review",
    "summary": "NIH stops rivaroxaban arm in CAPTIVA stroke trial after safety events and futility signal; study continues with other treatment groups.",
    "url": "https://finnhub.io/api/news?id=9a0bf970c3dc772a459fe5a851352ea2916f83e0c8c48bb889a8d4aca09ad3ef",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770823421,
      "headline": "NIH Stops Johnson & Johnson's Blood Thinner Drug Arm In Stroke Trial After Safety Review",
      "id": 139055681,
      "image": "https://cdn.benzinga.com/files/images/story/2026/02/11/Johnson--Johnson.jpeg?width=2048&height=1536",
      "related": "JNJ",
      "source": "Benzinga",
      "summary": "NIH stops rivaroxaban arm in CAPTIVA stroke trial after safety events and futility signal; study continues with other treatment groups.",
      "url": "https://finnhub.io/api/news?id=9a0bf970c3dc772a459fe5a851352ea2916f83e0c8c48bb889a8d4aca09ad3ef"
    }
  },
  {
    "ts": null,
    "headline": "VYM’s S&P Beating Dividend Survived Two Decades Without Missing a Payment",
    "summary": "Vanguard High Dividend Yield Index Fund ETF Shares (NYSEARCA:VYM) generates income by holding a diversified portfolio of dividend-paying U.S. stocks and passing those dividends directly to shareholders. With $88.5 billion in assets and an ultra-low 0.06% expense ratio, VYM offers cost-efficient exposure to companies that consistently return cash to investors. The fund currently yields 2.45%, ... VYM’s S&P Beating Dividend Survived Two Decades Without Missing a Payment",
    "url": "https://finnhub.io/api/news?id=5d0fd5d96fdb1d5a6896041a97f4abba9e467d381d1a80a18fc8714408f33844",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770816202,
      "headline": "VYM’s S&P Beating Dividend Survived Two Decades Without Missing a Payment",
      "id": 139045041,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Vanguard High Dividend Yield Index Fund ETF Shares (NYSEARCA:VYM) generates income by holding a diversified portfolio of dividend-paying U.S. stocks and passing those dividends directly to shareholders. With $88.5 billion in assets and an ultra-low 0.06% expense ratio, VYM offers cost-efficient exposure to companies that consistently return cash to investors. The fund currently yields 2.45%, ... VYM’s S&P Beating Dividend Survived Two Decades Without Missing a Payment",
      "url": "https://finnhub.io/api/news?id=5d0fd5d96fdb1d5a6896041a97f4abba9e467d381d1a80a18fc8714408f33844"
    }
  },
  {
    "ts": null,
    "headline": "Can Pfizer's New & Acquired Drugs Offset Its Looming Patent Cliff?",
    "summary": "PFE bets on new and acquired drugs to reignite growth as COVID sales fade and a 2026-2030 patent cliff threatens key blockbusters.",
    "url": "https://finnhub.io/api/news?id=e63a3df62afc845d15449875b0c97ba9473a738a02341da68a397776a2693a6d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770815340,
      "headline": "Can Pfizer's New & Acquired Drugs Offset Its Looming Patent Cliff?",
      "id": 139045076,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "PFE bets on new and acquired drugs to reignite growth as COVID sales fade and a 2026-2030 patent cliff threatens key blockbusters.",
      "url": "https://finnhub.io/api/news?id=e63a3df62afc845d15449875b0c97ba9473a738a02341da68a397776a2693a6d"
    }
  },
  {
    "ts": null,
    "headline": "JEPI’s 8% Yield Is Impressive, But Has a Hidden Cost Most Retirees Miss",
    "summary": "The promise sounds almost too good: invest your nest egg in JPMorgan Equity Premium Income ETF (NYSEARCA:JEPI), collect 8.21% in monthly distributions, and live comfortably off the income. For retirees tired of bond yields that barely keep pace with inflation, JEPI has become a popular alternative. But retiring on this ETF alone is more complicated ... JEPI’s 8% Yield Is Impressive, But Has a Hidden Cost Most Retirees Miss",
    "url": "https://finnhub.io/api/news?id=441621c00f64190f7f457e8ca6398b308edae1cedb6cf44c20e06fb41ec25ec5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770814139,
      "headline": "JEPI’s 8% Yield Is Impressive, But Has a Hidden Cost Most Retirees Miss",
      "id": 139042197,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The promise sounds almost too good: invest your nest egg in JPMorgan Equity Premium Income ETF (NYSEARCA:JEPI), collect 8.21% in monthly distributions, and live comfortably off the income. For retirees tired of bond yields that barely keep pace with inflation, JEPI has become a popular alternative. But retiring on this ETF alone is more complicated ... JEPI’s 8% Yield Is Impressive, But Has a Hidden Cost Most Retirees Miss",
      "url": "https://finnhub.io/api/news?id=441621c00f64190f7f457e8ca6398b308edae1cedb6cf44c20e06fb41ec25ec5"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers: Walking Blindfolded To A $30 Billion Patent Cliff",
    "summary": "All eyes should be on Bristol-Myers' upcoming $30B patent cliff as the Growth portfolio lost significant potential. Read why BMY stock is downgraded to Hold.",
    "url": "https://finnhub.io/api/news?id=998c1f1316cfb5204c61b1045a95674a0852fcfbc9266365137c83389a04252f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770804000,
      "headline": "Bristol-Myers: Walking Blindfolded To A $30 Billion Patent Cliff",
      "id": 139044801,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/158759380/image_158759380.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "All eyes should be on Bristol-Myers' upcoming $30B patent cliff as the Growth portfolio lost significant potential. Read why BMY stock is downgraded to Hold.",
      "url": "https://finnhub.io/api/news?id=998c1f1316cfb5204c61b1045a95674a0852fcfbc9266365137c83389a04252f"
    }
  },
  {
    "ts": null,
    "headline": "[Latest] Global Cell Therapy Raw Materials Market Size/Share Worth USD 29.3 Billion by 2035 at a 18.9% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)",
    "summary": "[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Cell Therapy Raw Materials Market size & share revenue was valued at approximately USD 5.2 Billion in 2025 and is expected to reach USD 6.1 Billion in 2026 and is expected to reach around USD 29.3 Billion by 2035, at a CAGR of 18.9% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Thermo Fisher Scientifi",
    "url": "https://finnhub.io/api/news?id=c22cd33e3631ef80746530b35aceb063fc0500a94ebd206fe4f30c49608849e9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770798600,
      "headline": "[Latest] Global Cell Therapy Raw Materials Market Size/Share Worth USD 29.3 Billion by 2035 at a 18.9% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)",
      "id": 139040455,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Cell Therapy Raw Materials Market size & share revenue was valued at approximately USD 5.2 Billion in 2025 and is expected to reach USD 6.1 Billion in 2026 and is expected to reach around USD 29.3 Billion by 2035, at a CAGR of 18.9% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Thermo Fisher Scientifi",
      "url": "https://finnhub.io/api/news?id=c22cd33e3631ef80746530b35aceb063fc0500a94ebd206fe4f30c49608849e9"
    }
  },
  {
    "ts": null,
    "headline": "Is Johnson & Johnson a Buy, Sell, or Hold in 2026?",
    "summary": "This reliable dividend payer may be just what the doctor ordered.",
    "url": "https://finnhub.io/api/news?id=27367bf9f5786e13803385a901a0968648208681ff6b747350c847b60437bce6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770779100,
      "headline": "Is Johnson & Johnson a Buy, Sell, or Hold in 2026?",
      "id": 139038857,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "This reliable dividend payer may be just what the doctor ordered.",
      "url": "https://finnhub.io/api/news?id=27367bf9f5786e13803385a901a0968648208681ff6b747350c847b60437bce6"
    }
  },
  {
    "ts": null,
    "headline": "How Recent Analyst Shifts Are Rewriting The Story For Johnson & Johnson (NYSE:JNJ)",
    "summary": "What Is Driving the New Fair Value Estimate for Johnson & Johnson? The fair value estimate for Johnson & Johnson has shifted from about US$224.09 to roughly US$231.25 per share, and the revenue growth assumption has moved from about 5.81% to roughly 6.04%, with a small change in the discount rate from 6.96% to 6.98% to reflect a slightly different view of risk. Recent Street research has tilted more positive, with several firms raising price targets and one new initiation that calls the stock...",
    "url": "https://finnhub.io/api/news?id=c54c0599de83a4829853077da754acc138912855ab8c864b5d541e3b289f771c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770769052,
      "headline": "How Recent Analyst Shifts Are Rewriting The Story For Johnson & Johnson (NYSE:JNJ)",
      "id": 139038308,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "What Is Driving the New Fair Value Estimate for Johnson & Johnson? The fair value estimate for Johnson & Johnson has shifted from about US$224.09 to roughly US$231.25 per share, and the revenue growth assumption has moved from about 5.81% to roughly 6.04%, with a small change in the discount rate from 6.96% to 6.98% to reflect a slightly different view of risk. Recent Street research has tilted more positive, with several firms raising price targets and one new initiation that calls the stock...",
      "url": "https://finnhub.io/api/news?id=c54c0599de83a4829853077da754acc138912855ab8c864b5d541e3b289f771c"
    }
  }
]